Adrenaline for the treatment of anaphylaxis: cochrane systematic review

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. Adrenaline is recommended as the initial treatment of choice for anaphylaxis. To assess the benefits and harms of adrenaline in the treatment of anaphylaxis. We searched the Cochrane Central Register of Controlled...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Allergy Ročník 64; číslo 2; s. 204 - 212
Hlavní autori: Sheikh, A, Shehata, Y.A, Brown, S.G.A, Simons, F.E.R
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Oxford, UK Oxford, UK : Blackwell Publishing Ltd 01.02.2009
Blackwell Publishing Ltd
Blackwell
Predmet:
administration & dosage
adrenaline
Adrenergic Agonists
Adrenergic Agonists - administration & dosage
Adrenergic Agonists - immunology
Adrenergic Agonists - therapeutic use
Allergies
anaphylaxis
Anaphylaxis - drug therapy
Anaphylaxis - immunology
Biological and medical sciences
Clinical trials
cochrane
Databases, Factual
Drug Administration Routes
drug therapy
effectiveness
Emergency medical care
epinephrine
Epinephrine - administration & dosage
Epinephrine - immunology
Epinephrine - therapeutic use
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
immunology
Medical sciences
Medical treatment
Prescription drugs
Randomized Controlled Trials as Topic
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
systematic review
therapeutic use
Epinephrine
Allergy
Immunopathology
Dermatology
Evidence-based practice
Systematic review
Catecholamine
Evidence-based medicine
Anaphylaxis
Immunology
Treatment
Efficiency
adrenaline; anaphylaxis; cochrane; effectiveness
Neurotransmitter
ISSN:0105-4538, 1398-9995, 1398-9995, 0108-1675
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. Adrenaline is recommended as the initial treatment of choice for anaphylaxis. To assess the benefits and harms of adrenaline in the treatment of anaphylaxis. We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, Issue 1), MEDLINE (1966 to March 2007), EMBASE (1966 to March 2007), CINAHL (1982 to March 2007), BIOSIS (to March 2007), ISI Web of Knowledge (to March 2007) and LILACS (to March 2007). We also searched websites listing ongoing trials: http://www.clinicaltrials.gov/, http://www.controlledtrials.com and http://www.actr.org.au/ and contacted pharmaceutical companies and international experts in anaphylaxis in an attempt to locate unpublished material. Randomized and quasi-randomized controlled trials comparing adrenaline with no intervention, placebo or other adrenergic agonists were eligible for inclusion. Two authors independently assessed articles for inclusion. We found no studies that satisfied the inclusion criteria. On the basis of this review, we are unable to make any new recommendations on the use of adrenaline for the treatment of anaphylaxis. In the absence of appropriate trials, we recommend, albeit on the basis of less than optimal evidence, that adrenaline administration by intramuscular injection should still be regarded as first-line treatment for the management of anaphylaxis.
Bibliografia:http://dx.doi.org/10.1111/j.1398-9995.2008.01926.x
ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Literature Review-2
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Feature-2
ObjectType-Review-3
ObjectType-Undefined-4
ISSN:0105-4538
1398-9995
1398-9995
0108-1675
DOI:10.1111/j.1398-9995.2008.01926.x